Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N6- or O6-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates

Journal of Medicinal Chemistry
2011.0

Abstract

Human N(6)-methyl-AMP/dAMP aminohydrolase has been shown to be involved in metabolism of pharmacologically important N(6)-substituted purine nucleosides and 5'-monophosphate prodrugs thereof. This enzyme was cloned and expressed in E. coli, and mass spectroscopic analysis followed by amino acid sequence analyses indicated that the protein was adenosine deaminase-like protein isoform 1 (ADAL1). An extensive structure-activity relationship study showed that ADAL1 was able to catalyze removal of different alkyl groups not only from N(6)-substituted purine or 2-aminopurine nucleoside monophosphates but also from O(6)-substituted compounds. The ADAL1 activity was susceptible to modifications in the phosphate moiety but not to changes in the sugar moiety. Overall, our data indicated that ADAL1 specifically acts at the 6-position of purine and 2-aminopurine nucleoside monophosphates. Our results may help designing of new therapeutic nucleoside/nucleotide prodrugs with desired metabolic profiles. Furthermore, amino acid sequence analysis in conjunction with crystallographic data and metal analysis suggested that ADAL1 contains a catalytic zinc ion. Finally, a potential physiological role of ADAL1 is discussed.

Knowledge Graph

Similar Paper

Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N<sup>6</sup>- or O<sup>6</sup>-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates
Journal of Medicinal Chemistry 2011.0
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity
Journal of Medicinal Chemistry 1991.0
Novel 6-alkoxypurine 2',3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus
Journal of Medicinal Chemistry 1993.0
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs
Journal of Medicinal Chemistry 1991.0
Design and synthesis of 6-fluoropurine acyclonucleosides : potential prodrugs of acyclovir and ganciclovir
Bioorganic &amp; Medicinal Chemistry Letters 1994.0
A Unique Ring-Expanded Acyclic Nucleoside Analogue that Inhibits Both Adenosine Deaminase (ADA) and Guanine Deaminase (GDA; Guanase): Synthesis and Enzyme Inhibition Studies of 4,6-Diamino-8H-1-hydroxyethoxymethyl-8-iminoimidazo[4,5-e][1,3]diazepine
Bioorganic &amp; Medicinal Chemistry Letters 2001.0
Rational Design of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors: Predicting Enzyme Conformational Change and Metabolism
Journal of Medicinal Chemistry 2005.0
Adenosine deaminase inhibitors. Synthesis of deaza analogs of erythro-9-(2-hydroxy-3-nonyl) adenine
Journal of Medicinal Chemistry 1984.0
Investigations into the Origin of the Molecular Recognition of Several Adenosine Deaminase Inhibitors
Journal of Medicinal Chemistry 2011.0
Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines
Bioorganic &amp; Medicinal Chemistry 2011.0